PortalPublikationenSelection and counterselection of the rtI233V adefovir resis...

Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.

Standard

Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. / Schildgen, Oliver; Olotu, Cynthia; Funk, Anneke; Zöllner, B.; Helm, Martin; Rockstroh, Jürgen Kurt; Sirma, Hüseyin.

in: J CLIN MICROBIOL, Jahrgang 48, Nr. 2, 2, 2010, S. 631-634.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schildgen, O, Olotu, C, Funk, A, Zöllner, B, Helm, M, Rockstroh, JK & Sirma, H 2010, 'Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.', J CLIN MICROBIOL, Jg. 48, Nr. 2, 2, S. 631-634. <http://www.ncbi.nlm.nih.gov/pubmed/20007398?dopt=Citation>

APA

Schildgen, O., Olotu, C., Funk, A., Zöllner, B., Helm, M., Rockstroh, J. K., & Sirma, H. (2010). Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. J CLIN MICROBIOL, 48(2), 631-634. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20007398?dopt=Citation

Vancouver

Schildgen O, Olotu C, Funk A, Zöllner B, Helm M, Rockstroh JK et al. Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. J CLIN MICROBIOL. 2010;48(2):631-634. 2.

Bibtex

@article{83a84f93bbde4c1bb4506d5a8db66c2a,
title = "Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.",
abstract = "Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation. Here, we describe two further patients with chronic HBV infection who were found to develop the rtI233V mutation after initiation of ADF therapy. These patients represent the first cases known so far in which the rtI233V ADF resistance mutation evolved under persistent HBV replication during HBV therapy with ADF. Interestingly, one of the previously described patients, who was initially successfully switched from ADF to tenofovir (TDF) and became virologically suppressed subsequently, experienced a moderate but remarkable rebound of HBV viremia after switching from TDF to entecavir, due to the emergence of renal toxicity. Thus, we provide evidence for the selection and counterselection of the rtI233V ADF resistance mutation during antiviral therapy.",
author = "Oliver Schildgen and Cynthia Olotu and Anneke Funk and B. Z{\"o}llner and Martin Helm and Rockstroh, {J{\"u}rgen Kurt} and H{\"u}seyin Sirma",
year = "2010",
language = "English",
volume = "48",
pages = "631--634",
journal = "J CLIN MICROBIOL",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",

}

RIS

TY - JOUR

T1 - Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.

AU - Schildgen, Oliver

AU - Olotu, Cynthia

AU - Funk, Anneke

AU - Zöllner, B.

AU - Helm, Martin

AU - Rockstroh, Jürgen Kurt

AU - Sirma, Hüseyin

PY - 2010

Y1 - 2010

N2 - Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation. Here, we describe two further patients with chronic HBV infection who were found to develop the rtI233V mutation after initiation of ADF therapy. These patients represent the first cases known so far in which the rtI233V ADF resistance mutation evolved under persistent HBV replication during HBV therapy with ADF. Interestingly, one of the previously described patients, who was initially successfully switched from ADF to tenofovir (TDF) and became virologically suppressed subsequently, experienced a moderate but remarkable rebound of HBV viremia after switching from TDF to entecavir, due to the emergence of renal toxicity. Thus, we provide evidence for the selection and counterselection of the rtI233V ADF resistance mutation during antiviral therapy.

AB - Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation. Here, we describe two further patients with chronic HBV infection who were found to develop the rtI233V mutation after initiation of ADF therapy. These patients represent the first cases known so far in which the rtI233V ADF resistance mutation evolved under persistent HBV replication during HBV therapy with ADF. Interestingly, one of the previously described patients, who was initially successfully switched from ADF to tenofovir (TDF) and became virologically suppressed subsequently, experienced a moderate but remarkable rebound of HBV viremia after switching from TDF to entecavir, due to the emergence of renal toxicity. Thus, we provide evidence for the selection and counterselection of the rtI233V ADF resistance mutation during antiviral therapy.

M3 - SCORING: Journal article

VL - 48

SP - 631

EP - 634

JO - J CLIN MICROBIOL

JF - J CLIN MICROBIOL

SN - 0095-1137

IS - 2

M1 - 2

ER -